{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:00:18Z","timestamp":1773280818502,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.coph.2012.09.012","type":"journal-article","created":{"date-parts":[[2012,10,12]],"date-time":"2012-10-12T18:15:41Z","timestamp":1350065741000},"page":"50-55","source":"Crossref","is-referenced-by-count":50,"title":["Pharmacological management of ocular hypertension: current approaches and future prospective"],"prefix":"10.1016","volume":"13","author":[{"given":"Claudio","family":"Bucolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Salomone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Drago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Reibaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio Giacinto","family":"Uva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2012.09.012_bib0005","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ophtha.2007.04.003","article-title":"Barbados eye studies group incident open-angle glaucoma and intraocular pressure","volume":"114","author":"Nemesure","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coph.2012.09.012_bib0010","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1167\/iovs.09-4918","article-title":"Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma","volume":"51","author":"Spiga","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0015","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1167\/iovs.12-9483o","article-title":"Advances in glaucoma treatment and management: gene therapy","volume":"53","author":"Borr\u00e1s","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.pharmthera.2006.11.003","article-title":"Melatonin receptors in the eye: location, second messengers and role in ocular physiology","volume":"113","author":"Alarma-Estrany","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.coph.2012.09.012_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-079X.2010.00816.x","article-title":"The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential","volume":"50","author":"Agorastos","year":"2011","journal-title":"J Pineal Res"},{"key":"10.1016\/j.coph.2012.09.012_bib0030","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1124\/jpet.110.178319","article-title":"Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits","volume":"337","author":"Alarma-Estrany","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2012.09.012_bib0035_1","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.2174\/092986712801323234","article-title":"Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues","volume":"19","author":"Crooke","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.coph.2012.09.012_bib0040_1","doi-asserted-by":"crossref","unstructured":"Musumeci T, Bucolo C, Carbone C, Pignatello R, Drago F, Puglisi G: Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. Int J Pharm 2012, in press.","DOI":"10.1016\/j.ijpharm.2012.10.014"},{"key":"10.1016\/j.coph.2012.09.012_bib0045_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neulet.2011.02.056","article-title":"Removal of melatonin receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouse","volume":"494","author":"Alcantara-Contreras","year":"2011","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.coph.2012.09.012_bib0050","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/qjmed\/hcg085","article-title":"Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension","volume":"96","author":"Rauz","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.coph.2012.09.012_bib0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/jop.2008.0120","article-title":"In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye","volume":"25","author":"Anderson","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.coph.2012.09.012_bib0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.survophthal.2008.08.010","article-title":"Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction","volume":"53","author":"Toris","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.coph.2012.09.012_bib0065","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.bjp.0707434","article-title":"Prostamides (prostaglandin-ethanolamides) and their pharmacology","volume":"153","author":"Woodward","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coph.2012.09.012_bib0070","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3109\/02713683.2011.593725","article-title":"A phase 2, randomized, dose\u2013response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension","volume":"36","author":"Schachar","year":"2011","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.coph.2012.09.012_bib0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.exer.2011.03.001","article-title":"Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2\u03b1 agonist, in preclinical models","volume":"93","author":"Krauss","year":"2011","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2012.09.012_bib0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.exer.2011.02.015","article-title":"Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma","volume":"93","author":"Prasanna","year":"2011","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2012.09.012_bib0085_1","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1167\/iovs.10-6342","article-title":"Elastic modulus determination of normal and glaucomatous human trabecular meshwork","volume":"52","author":"Last","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0090_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1167\/iovs.10-5265","article-title":"Effects of fasudil, a rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits","volume":"52","author":"Sugiyama","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0095","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1167\/iovs.12-9483m","article-title":"Advances in glaucoma treatment and management: outflow drugs","volume":"53","author":"Kaufman","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0100","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1167\/iovs.05-0421","article-title":"Modulation of conventional outflow facility by the adenosine A agonist N6-cyclohexyladenosine","volume":"46","author":"Crosson","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0105","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1159\/000335865","article-title":"Mechanisms of ATP release, the enabling step in purinergic dynamics","volume":"28","author":"Li","year":"2011","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.coph.2012.09.012_bib0110","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.exer.2009.10.001","article-title":"Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species","volume":"90","author":"Wang","year":"2010","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2012.09.012_bib0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.drudis.2011.10.007","article-title":"Pharmacological and therapeutic effects of A3 adenosine receptor agonists","volume":"17","author":"Fishman","year":"2012","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.coph.2012.09.012_bib0120","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1167\/iovs.04-0651","article-title":"CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility","volume":"46","author":"Zhong","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0125","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/sj.bjp.0707495","article-title":"Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells","volume":"152","author":"McIntosh","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coph.2012.09.012_bib0130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1586\/17469899.3.4.457","article-title":"Endogenous bioactive lipids and the regulation of conventional outflow facility","volume":"3","author":"Wan","year":"2008","journal-title":"Expert Rev Ophthalmol"},{"key":"10.1016\/j.coph.2012.09.012_bib0135","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1167\/iovs.05-0729","article-title":"Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility","volume":"47","author":"Njie","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0140","first-page":"290","article-title":"CB1 cannabinoid receptor-mediated changes of trabecular meshwork cellular properties","volume":"12","author":"Kumar","year":"2006","journal-title":"Mol Vis"},{"key":"10.1016\/j.coph.2012.09.012_bib0145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/jop.2007.0074","article-title":"Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action","volume":"24","author":"Oltmanns","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.coph.2012.09.012_bib0150_1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/OPTH.S15971","article-title":"Novel ocular antihypertensive compounds in clinical trials","volume":"5","author":"Chen","year":"2011","journal-title":"Clinical Ophthalmology"},{"key":"10.1016\/j.coph.2012.09.012_bib0155_1","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.1167\/iovs.10-7057","article-title":"Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial","volume":"52","author":"Gagliano","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0160","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1054\/plef.2001.0349","article-title":"Anandamide receptors","volume":"66","author":"Di Marzo","year":"2002","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.coph.2012.09.012_bib0165_1","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1167\/iovs.11-9294","article-title":"Effects of palmitoylethanolamide on aqueous humor outflow","volume":"53","author":"Kumar","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0170","first-page":"1040","article-title":"Serotonin receptor subtype mRNA expression in human ocular tissues determined by RT-PCR","volume":"12","author":"Sharif","year":"2006","journal-title":"Mol Vis"},{"key":"10.1016\/j.coph.2012.09.012_bib0175","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.exer.2008.10.003","article-title":"Cabergoline: pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes","volume":"88","author":"Sharif","year":"2009","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2012.09.012_bib0180_1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2174\/138945010791591278","article-title":"Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action: novel drug targets for glaucoma treatment","volume":"11","author":"Sharif","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.coph.2012.09.012_bib0185_1","doi-asserted-by":"crossref","first-page":"e44316","DOI":"10.1371\/journal.pone.0044316","article-title":"Homology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluation","volume":"7","author":"Platania","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2012.09.012_bib0190","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.coph.2012.09.012_bib0195_1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.bcp.2011.11.031","article-title":"Dopamine-3 receptor modulates intraocular pressure: implications for glaucoma","volume":"83","author":"Bucolo","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2012.09.012_bib0260","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/112067210301300407","article-title":"Effects of ibopamine eye drops on intraocular pressure and aqueous humor flow in healthy volunteers and patients with open-angle glaucoma","volume":"13","author":"Azevedo","year":"2003","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.coph.2012.09.012_bib0205","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0022-3565(24)39290-0","article-title":"Mechanisms and sites of ocular action of 7-hydroxy-2 dipropylaminotetralin: a dopamine(3) receptor agonist","volume":"293","author":"Chu","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2012.09.012_bib0210","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1159\/000335866","article-title":"Guanylate cyclase activators, cell volume changes and IOP reduction","volume":"28","author":"Ellis","year":"2011","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.coph.2012.09.012_bib0215","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/108076803322660440","article-title":"Topical application of a nitric oxide synthase inhibitor reduces intraocular pressure in rabbits with experimental glaucoma","volume":"19","author":"Giuffrida","year":"2003","journal-title":"J Ocular Pharmacol"},{"key":"10.1016\/j.coph.2012.09.012_bib0220","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1076\/ceyr.26.2.119.14511","article-title":"Nitric oxide and cyclic GMP enhance aqueous humor outflow facility in rabbits","volume":"26","author":"Kotikoski","year":"2003","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.coph.2012.09.012_bib0225","doi-asserted-by":"crossref","first-page":"9438","DOI":"10.1167\/iovs.11-7839","article-title":"eNOS, a pressure-dependent regulator of intraocular pressure","volume":"52","author":"Stamer","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0230","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1006\/exer.2001.1050","article-title":"Effects of nitric oxide synthase inhibition on ciliary blood flow, aqueous production and intraocular pressure","volume":"73","author":"Kiel","year":"2001","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2012.09.012_bib0235","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1358\/dnp.2010.23.7.1484488","article-title":"Therapeutic potential of nitric oxide modulation in ocular diseases","volume":"23","author":"Bucolo","year":"2010","journal-title":"Drug News Perspectives"},{"key":"10.1016\/j.coph.2012.09.012_bib0240","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1167\/iovs.09-4530","article-title":"Episcleral venous pressure responses to topical nitroprusside and N-nitro-l-arginine methyl ester","volume":"51","author":"Zamora","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2012.09.012_bib0245","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/jop.2006.101","article-title":"Hemin, an inducer of heme oxygenase-1, lowers intraocular pressure in rabbits","volume":"23","author":"Privitera","year":"2007","journal-title":"J Ocular Pharmacol Ther"},{"key":"10.1016\/j.coph.2012.09.012_bib0250","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/bjo.2007.137034","article-title":"A water-soluble carbon monoxide-releasing molecule (CORM-3) lowers intraocular pressure in rabbits","volume":"93","author":"Stagni","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.coph.2012.09.012_bib0255_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pharmthera.2011.01.013","article-title":"Carbon monoxide and the eye: implications for glaucoma therapy","volume":"130","author":"Bucolo","year":"2011","journal-title":"Pharmacol Ther"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489212001944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489212001944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T15:44:30Z","timestamp":1744386270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489212001944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1471489212001944"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2012.09.012","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}